Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified? [0.03%]
关于戈谢病I型和3b型的酶替代疗法的价值评估：能否扩大用药范围？
Waranya Rattanavipapong,Thunyarat Anothaisintawee,Wanrudee Isaranuwatchai et al.
Waranya Rattanavipapong et al.
Background and objectives: The Health Intervention and Technology Assessment Program was commissioned to conduct a cost-utility and budget impact analysis of enzyme replacement therapy (ERT) for Gaucher disease types 1 an...
Using Generative Artificial Intelligence in Health Economics and Outcomes Research: A Primer on Techniques and Breakthroughs [0.03%]
用于健康经济与结果研究的生成式人工智能：技术与突破简介
Tim Reason,Sven Klijn,Will Rawlinson et al.
Tim Reason et al.
The emergence of generative artificial intelligence (GenAI) offers the potential to enhance health economics and outcomes research (HEOR) by streamlining traditionally time-consuming and labour-intensive tasks, such as literature reviews, d...
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in High-Risk Older Adults in Japan [0.03%]
莫努匹拉韦治疗日本高危老年新冠门诊患者的成本效益分析：与最优支持护理相比
Hardik Goswami,Atsushi Tajima,Taizo Matsuki et al.
Hardik Goswami et al.
Objectives: This analysis aimed to evaluate the cost effectiveness of molnupiravir versus best supportive care for the treatment of older adult patients (aged ≥ 65 years) in Japan with mild to moderate COVID-19 who are a...
A Systematic Literature Review of the Economic and Healthcare Resource Utilization Burden of Relapsed/Refractory Follicular Lymphoma [0.03%]
复发/难治性滤泡淋巴瘤的经济和医疗资源利用负担的系统评价文献回顾
Bijal Shah,Mei Xue,Wesley Furnback et al.
Bijal Shah et al.
Objective: To quantify the economic or healthcare resource utilization (HCRU) burden and examine the value of interventions for relapsed or refractory (R/R) follicular lymphoma (FL). ...
Indirect Treatment Comparisons in EUnetHTA Relative Effectiveness Assessments: Learnings and Recommendations for the Implementation of EU Joint Clinical Assessments [0.03%]
基于EUnetHTA疗效评估的间接治疗比较对EU联合临床评估实施的启示与建议
Sophie van Beekhuizen,Menglu Che,Loraine Monfort et al.
Sophie van Beekhuizen et al.
Background: Beginning in January 2025, all new active substances must undergo evaluation of relative clinical effectiveness through European Union (EU) joint clinical assessments (JCAs). In the absence of head-to-head dat...
Cost-Effectiveness of Ultrasound Renal Denervation for Resistant Hypertension in Belgium, France and The Netherlands [0.03%]
比利时、法国和荷兰针对难治性高血压的超声肾去神经术的成本效益分析
Rod S Taylor,Kaylie Metcalfe,Antoine Cremer et al.
Rod S Taylor et al.
Background: Endovascular ultrasound renal denervation (uRDN) with the Paradise System has emerged as an adjunctive treatment option for the management of uncontrolled resistant hypertension (rHTN). This study assesses the...
Patient Validation of Estimation of Health Utility Values in Alopecia Areata [0.03%]
患者验证脱发的健康效用价值估算
Caleb Dixon,Thomas Price,Elin Gruffydd et al.
Caleb Dixon et al.
Background: Current patient-reported burden measures, which guide decision-making, may not be sensitive to pertinent impacts of alopecia areata (AA). The UK public previously valued patient/caregiver vignettes using the t...
Optimizing Diabetic Retinopathy Screening at Primary Health Centres in India: A Cost-Effectiveness Analysis [0.03%]
印度初级保健中心糖尿病视网膜病变筛查的优化：一项成本效益分析
Neha Purohit,Parul Chawla Gupta,Sandeep Buttan et al.
Neha Purohit et al.
Background: The eye care package under the Ayushman Bharat comprehensive primary healthcare programme includes annual population-based screening for diabetic retinopathy (DR) using non-mydriatic fundus cameras at the prim...
Cost-Effectiveness of Using Conditional Economic Incentives to Improve Pre-exposure Prophylaxis Adherence Among Male Sex Workers [0.03%]
有条件经济激励提高男男性行为者暴露前预防用药依从性的成本效果分析
Carlos Chivardi,Alejandro Zamudio-Sosa,Marta Wilson-Barthes et al.
Carlos Chivardi et al.
Introduction: Conditional economic incentives can improve medication-taking behaviors among populations at risk of contracting human immunodeficiency virus (HIV). However, there are no data on the cost-effectiveness of in...
Measuring the Socioeconomic Impact of Cancer: A Systematic Review and Standardized Assessment of Patient-Reported Outcomes (PRO) Instruments [0.03%]
系统综述和患者报告结果(PRO)工具的标准化评估癌症的社会经济影响测量
Phu Duy Pham,Jasper Ubels,Rachel Eckford et al.
Phu Duy Pham et al.
Background: A number of instruments have been developed to measure the socioeconomic impact (SEI) of cancer. A standardized comparison of the quality and content validity of these instruments is lacking. This study aimed ...